Open Access. Powered by Scholars. Published by Universities.®
Medicinal and Pharmaceutical Chemistry Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Brain (2)
- CYP3A (2)
- Cancer (2)
- Microsomes (2)
- Midazolam hydroxylation (2)
-
- Pneumonia (2)
- Vaccines (2)
- 5-HT (1)
- Amphiphilic cyclic peptide (1)
- Analytical Methods (1)
- Androgen Receptor (1)
- Anti-depressant (1)
- Anti-tuberculosis activity (1)
- Anti-viral drugs (1)
- Antibacterial activity (1)
- Antibacterial resistance (1)
- Anticancer (1)
- Antifolate (1)
- Antioxidative activity (1)
- Antiproliferative (1)
- Antiviral (1)
- Apigenin (1)
- BOl (1)
- Bioinformatics (1)
- Biological transport (1)
- Biomaterial (1)
- Blood–brain barrier permeability (1)
- COVID-19 (1)
- COX-independent (1)
- Candida (1)
- Publication Year
Articles 31 - 32 of 32
Full-Text Articles in Medicinal and Pharmaceutical Chemistry
Antioxidation Activity Of Dhea And Its Mechanisms, Sun Yang, Han Rui
Antioxidation Activity Of Dhea And Its Mechanisms, Sun Yang, Han Rui
Pharmacy Faculty Articles and Research
Objective: The aim of this study was to determine the anti-oxidative activity of a new chemopreventive agent--dehydroepiandrosterone (DHEA), and the mechanisms of action by which DHEA protect the thymocytes and DNA from oxidative damage. Methods: Agarose gel electrophoresis, flow cytometry, single cel! gel electrophoresis, chemiluminescence assay, triazolyl blue tetrazolumbromide (MTT) colorimetry, and three dimensional collagen gel assay were used. Results: In agarose gel electrophoresis, 10 nmol/L DHEA blocked the typical DNA degradation (DNA Ladder) induced by H2O2. DHEA 2. 5 nmol/L and 10 nmol/L both significantly decreased the percentage of characteristic apoptotic DNA …
What Is The Risk Of Teratogenicity With The Use Of Selective Serotonin Reuptake Inhibitors During Pregnancy?, Michael Z. Wincor, Mary Gutierrez, Ann Nguyen
What Is The Risk Of Teratogenicity With The Use Of Selective Serotonin Reuptake Inhibitors During Pregnancy?, Michael Z. Wincor, Mary Gutierrez, Ann Nguyen
Pharmacy Faculty Articles and Research
"The lifetime prevalence of major depressive disorder in women is 10 to 25%, with an average age of onset in the mid-20s.1 Over the nine years that the selective serotonin reuptake inhibitors (SSRis) have been available, for many prescribers, they have become first-line agents in the treatment of depression. In addition, sorne of them are also being used in the treatment of obsessive- compulsive disorder and panic disorder. In light of these facts, itis not unlikely that women of childbearing age would be treated with one of the SSRis. In considering the risks of exposing a fetus to an SSRI, …